At Novartis, our company and our products are uniquely positioned to begin to shape a future without cancer. Our products are already improving the lives of patients with breast cancer, prostate cancer, multiple myeloma, carcinoid syndrome, chronic myeloid leukemia, and many other cancers. And our pipeline is overflowing with hope-inspiring medicines like small molecule tyrosine kinase inhibitors, anti-angiogenesis compounds and unique cytotoxics. Our staff includes some of the foremost oncology professionals in the world. Could you be the next?

It takes special people to work in oncology, and a special kind of company to support them. A company with the highest quality science, committed to oncology in words and actions, one with a full stable of recently launched oncology compounds and a robust pipeline of many more, one with dedicated oncology discovery and access to cutting edge genomics. Novartis Pharmaceuticals Corporation is that company.

At Novartis, we recognize that oncology is different from other therapeutic areas. That’s why Novartis Oncology operates as an independent business unit within Novartis Pharmaceuticals Corporation, enabling a flexible, entrepreneurial environment to exist, with ample access to the strong administrative and financial resources of the larger organization.

SUPERIOR PRODUCT DEVELOPMENT

Our leading edge scientific capabilities, including kinase inhibition and cutting edge genomics, are supported by a superior product development team. Many team members have come from the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI). This powerful combination has yielded three new drugs launched in 2001 alone. Each year, a minimum of two to three compounds or biological entities enters the clinic — compounds that achieve relevant biological endpoints in the intact animal at fully-tolerated doses that can be manufactured and formulated at a reasonable cost.

Consider the breadth of Novartis’ current portfolio, and consider the possibilities on the horizon:

Aredia® for treatment of osteolytic bone metastases in patients with multiple myeloma or breast cancer in conjunction with standard antineoplastic therapy, hypercalcemia of malignancy and Paget’s disease;

Desferal®, a potent iron-chelating agent for the treatment of acute iron intoxication and chronic iron overload;

Femara® for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Femara shows a demonstrated superiority over the current gold standard, tamoxifen;

Gleevec® oral therapy for the treatment of chronic myeloid leukemia. Gleevec has the fastest time to market of any cancer treatment, shipped within 24 hours of FDA approval;

Sandostatin LAR® Depot and Sandostatin® for long term treatment of symptoms in patients with metastatic carcinoid and vasoactive intestinal peptide-secreting tumors, and for the treatment of acromegaly;

Zometa® for the treatment of hypercalcemia of malignancy.

ON THE FAST TRACK

Novartis Oncology is uniquely positioned to grow faster than the industry. To help accomplish this, we’re seeking top talent from varied and diverse backgrounds who can make immediate contributions.
Functional areas range from medical doctors to scientific operations, from clinical research development to drug regulatory affairs, project management and research. We also seek the top tier of marketing, business development and licensing, finance, human resources and business analysis professionals.

In addition to the highly competitive compensation and benefits available to all Novartis employees, Novartis Oncology professionals can look forward to rewarding career development paths that include stretch assignments and structured classroom work led by professors from prestigious institutions, including Harvard, Columbia and Stanford. Through our affiliated companies, strategic alliances and external collaborations, Oncology professionals may also have the opportunity to work with the best and brightest of the nation’s major universities, biotechnology companies and research institutions, including the National Cancer Institute, Scripps Research Institute, and Dana Farber Cancer Institute.

**A FUTURE WITHOUT CANCER?**

Do you want to work with the best in the industry — in leading edge science, portfolio, product development, regulatory and research — with colleagues who have as high a potential as you do? Do you think a future without cancer is possible? Then, come join us at Novartis Oncology, and start your journey toward making these dreams a reality.

www.joinnovartis.com